Gabriel Marinheiro, Julyana Medeiros Dantas, Antonio Mutarelli, Artur Menegaz de Almeida, Gabriel de Almeida Monteiro, Djinane Spinosa Zerlotto, João Paulo Mota Telles
{"title":"布来哌唑治疗阿尔茨海默病躁动症的疗效和安全性:随机对照试验荟萃分析。","authors":"Gabriel Marinheiro, Julyana Medeiros Dantas, Antonio Mutarelli, Artur Menegaz de Almeida, Gabriel de Almeida Monteiro, Djinane Spinosa Zerlotto, João Paulo Mota Telles","doi":"10.1007/s10072-024-07576-8","DOIUrl":null,"url":null,"abstract":"<p><p>Recent randomized controlled trials (RCTs) have shown a benefit of brexpiprazole in managing agitation in patients with Alzheimer's disease (AD). However, its efficacy and safety remain unclear. We systematically searched PubMed, Embase, and Cochrane Library for RCTs comparing brexpiprazole with placebo in patients with agitation and AD. Three studies comprising 1,048 patients were included. In patients with agitation and AD, brexpiprazole significantly improved the Cohen-Mansfield Agitation Inventory total score (CMAI) at any dose (MD -3.05; 95% CI -5.12, -0.98; p < 0.01; I<sup>2</sup> = 19%) and at 2 mg (MD -4.36; 95% CI -7.02, -1.70; p < 0.01; I<sup>2</sup> = 0%) over 12 weeks. Brexpiprazole at any dose and 2 mg also showed benefit in the Clinical Global Impression - Severity of illness (CGI-S) score as related to agitation over 12 weeks (MD -0.20; 95% CI -0.36, -0.05; p < 0.01; I<sup>2</sup> = 35%). There is no significant difference between the groups in the incidence of at least one treatment-emergent adverse events (TEAEs; RR 1.14; 95% CI 0.95, 1.37; p = 0.16; I<sup>2</sup> = 45%) and all-cause mortality (RR 1.99; 95% CI 0.37, 10.84; p = 0.42; I<sup>2</sup> = 0%). Brexpiprazole at any dose significantly increased the Simpson-Angus Scale (SAS; MD 0.47; 95% CI 0.28, 0.66; p < 0.01). Our results suggest that brexpiprazole is more efficacious than placebo in the treatment of agitation in AD patients. Further studies are still necessary to confirm long-term effects of brexpiprazole.Prospero registry: CRD42023486694.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.\",\"authors\":\"Gabriel Marinheiro, Julyana Medeiros Dantas, Antonio Mutarelli, Artur Menegaz de Almeida, Gabriel de Almeida Monteiro, Djinane Spinosa Zerlotto, João Paulo Mota Telles\",\"doi\":\"10.1007/s10072-024-07576-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recent randomized controlled trials (RCTs) have shown a benefit of brexpiprazole in managing agitation in patients with Alzheimer's disease (AD). However, its efficacy and safety remain unclear. We systematically searched PubMed, Embase, and Cochrane Library for RCTs comparing brexpiprazole with placebo in patients with agitation and AD. Three studies comprising 1,048 patients were included. In patients with agitation and AD, brexpiprazole significantly improved the Cohen-Mansfield Agitation Inventory total score (CMAI) at any dose (MD -3.05; 95% CI -5.12, -0.98; p < 0.01; I<sup>2</sup> = 19%) and at 2 mg (MD -4.36; 95% CI -7.02, -1.70; p < 0.01; I<sup>2</sup> = 0%) over 12 weeks. Brexpiprazole at any dose and 2 mg also showed benefit in the Clinical Global Impression - Severity of illness (CGI-S) score as related to agitation over 12 weeks (MD -0.20; 95% CI -0.36, -0.05; p < 0.01; I<sup>2</sup> = 35%). There is no significant difference between the groups in the incidence of at least one treatment-emergent adverse events (TEAEs; RR 1.14; 95% CI 0.95, 1.37; p = 0.16; I<sup>2</sup> = 45%) and all-cause mortality (RR 1.99; 95% CI 0.37, 10.84; p = 0.42; I<sup>2</sup> = 0%). Brexpiprazole at any dose significantly increased the Simpson-Angus Scale (SAS; MD 0.47; 95% CI 0.28, 0.66; p < 0.01). Our results suggest that brexpiprazole is more efficacious than placebo in the treatment of agitation in AD patients. Further studies are still necessary to confirm long-term effects of brexpiprazole.Prospero registry: CRD42023486694.</p>\",\"PeriodicalId\":19191,\"journal\":{\"name\":\"Neurological Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10072-024-07576-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10072-024-07576-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
最近的随机对照试验(RCT)显示,布来哌唑在控制阿尔茨海默病患者(AD)的躁动方面有一定疗效。然而,其疗效和安全性仍不明确。我们系统地检索了 PubMed、Embase 和 Cochrane 图书馆中对躁动和 AD 患者进行布来哌唑与安慰剂比较的 RCT。共纳入了三项研究,包括 1,048 名患者。在任何剂量(MD -3.05;95% CI -5.12,-0.98;P 2 = 19%)和 2 毫克剂量(MD -4.36;95% CI -7.02,-1.70;P 2 = 0%)的躁动和注意力缺失症患者中,布雷克吡唑在 12 周内可显著改善 Cohen-Mansfield Agitation Inventory 总分(CMAI)。在12周内,任何剂量和2毫克的布雷哌唑也显示出与躁动相关的临床总体印象-疾病严重程度(CGI-S)评分的益处(MD -0.20;95% CI -0.36,-0.05;P 2 = 35%)。在至少一种治疗突发不良事件(TEAEs;RR 1.14;95% CI 0.95,1.37;P = 0.16;I2 = 45%)和全因死亡率(RR 1.99;95% CI 0.37,10.84;P = 0.42;I2 = 0%)的发生率方面,两组间无明显差异。任何剂量的布雷哌唑都能显著增加辛普森-安格斯量表(SAS;MD 0.47;95% CI 0.28,0.66;p
Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.
Recent randomized controlled trials (RCTs) have shown a benefit of brexpiprazole in managing agitation in patients with Alzheimer's disease (AD). However, its efficacy and safety remain unclear. We systematically searched PubMed, Embase, and Cochrane Library for RCTs comparing brexpiprazole with placebo in patients with agitation and AD. Three studies comprising 1,048 patients were included. In patients with agitation and AD, brexpiprazole significantly improved the Cohen-Mansfield Agitation Inventory total score (CMAI) at any dose (MD -3.05; 95% CI -5.12, -0.98; p < 0.01; I2 = 19%) and at 2 mg (MD -4.36; 95% CI -7.02, -1.70; p < 0.01; I2 = 0%) over 12 weeks. Brexpiprazole at any dose and 2 mg also showed benefit in the Clinical Global Impression - Severity of illness (CGI-S) score as related to agitation over 12 weeks (MD -0.20; 95% CI -0.36, -0.05; p < 0.01; I2 = 35%). There is no significant difference between the groups in the incidence of at least one treatment-emergent adverse events (TEAEs; RR 1.14; 95% CI 0.95, 1.37; p = 0.16; I2 = 45%) and all-cause mortality (RR 1.99; 95% CI 0.37, 10.84; p = 0.42; I2 = 0%). Brexpiprazole at any dose significantly increased the Simpson-Angus Scale (SAS; MD 0.47; 95% CI 0.28, 0.66; p < 0.01). Our results suggest that brexpiprazole is more efficacious than placebo in the treatment of agitation in AD patients. Further studies are still necessary to confirm long-term effects of brexpiprazole.Prospero registry: CRD42023486694.
期刊介绍:
Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles, short communications, editorials, reviews and letters to the editor. Original articles present the results of experimental or clinical studies in the neurosciences, while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology, Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews, meeting reports and announcements.